Rajaniemi H, Kauppila A, Rönnberg L, Selander K, Pystynen P
Acta Obstet Gynecol Scand Suppl. 1981;101:83-6. doi: 10.3109/00016348109157818.
LH(hCG) receptors were identified with [125I]hCG in 38 benign and 26 malignant ovarian tumors of the human ovary. Eighteen per cent of all the benign and 27% of all the malignant tumors were LH(hCG) receptor-positive. Four of 12 benign serous tumors and 3 of 17 benign mucinous tumors displayed definitive binding of [125I]hCG. Two Brenner tumors failed to bind [125I]hCG. Six of 21 malignant epithelial tumors displayed definitive binding of [125I]hCG. Only one out of 4 malignant granulosa cell tumors bound [125I]hCG, while the other sex cord stromal tumors as well as one dysgerminoma failed to bind [125I]hCG. LH(hCG) receptor content in the benign and malignant receptor-positive tumors was low compared with the normal ovarian tissue. The presence of LH(hCG) receptors in certain benign and malignant ovarian tumors may be a sign of the gonadotropic control of these tumors. The possible applications of these findings for the diagnosis and treatment of human ovarian tumors is discussed.
利用[125I]人绒毛膜促性腺激素(hCG)对38例人卵巢良性肿瘤和26例恶性肿瘤中的促黄体生成素(LH)(hCG)受体进行了鉴定。所有良性肿瘤中18%以及所有恶性肿瘤中27%的肿瘤为LH(hCG)受体阳性。12例良性浆液性肿瘤中有4例以及17例良性黏液性肿瘤中有3例显示出对[125I]hCG的明确结合。2例勃勒纳瘤未能结合[125I]hCG。21例恶性上皮性肿瘤中有6例显示出对[125I]hCG的明确结合。4例恶性颗粒细胞瘤中只有1例结合了[125I]hCG,而其他性索间质肿瘤以及1例无性细胞瘤未能结合[125I]hCG。与正常卵巢组织相比,良性和恶性受体阳性肿瘤中的LH(hCG)受体含量较低。某些良性和恶性卵巢肿瘤中LH(hCG)受体的存在可能是这些肿瘤受促性腺激素调控的一个标志。本文讨论了这些发现对人类卵巢肿瘤诊断和治疗的可能应用。